Content deleted Content added
Vortioxetine (talk | contribs) m Added SVG of structure |
JJMC89 bot III (talk | contribs) m Moving Category:4-Morpholinyl compunds to Category:4-Morpholinyl compounds per Wikipedia:Categories for discussion/Speedy |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
Line 47: | Line 48: | ||
[[Category:Benzochromenes]] |
[[Category:Benzochromenes]] |
||
[[Category:Carboxylate esters]] |
[[Category:Carboxylate esters]] |
||
[[Category: |
[[Category:4-Morpholinyl compounds]] |
||
[[Category:Carboxamides]] |
[[Category:Carboxamides]] |
||
[[Category:Diisopropylamino compounds]] |
[[Category:Diisopropylamino compounds]] |
Latest revision as of 13:19, 10 July 2023
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C38H60N2O5 |
Molar mass | 624.907 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
O-2694 is a drug that is a cannabinoid derivative. It has analgesic effects and is used in scientific research. Unlike most cannabinoids discovered to date, it is highly water-soluble, which gives it considerable advantages over many related drugs. It has high affinity for both CB1 and CB2 receptors, with Ki values of 3.7 nM at CB1 and 2.8 nM at CB2. However, it has complex pharmacokinetics as most of the administered dose is metabolised by hydrolysis of the ester link to the water-insoluble compound O-2372, thus producing a biphasic effects profile that is less suitable for research purposes than the related compound O-2545.[1]
See also[edit]
References[edit]
- ^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, et al. (September 2006). "Pharmacological characterization of novel water-soluble cannabinoids". The Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1230–9. doi:10.1124/jpet.106.104109. PMID 16757541. S2CID 14864925.